Meatable is a technology company.
Meatable is focused on creating real meat through innovative science and technology, aiming to provide sustainable solutions to the meat industry.
Meatable has raised $92.0M across 4 funding rounds.
Key people at Meatable.
Meatable has raised $92.0M in total across 4 funding rounds.
Meatable has raised $92.0M in total across 4 funding rounds.
Meatable's investors include BlueYard Capital, ZAKA Ventures, Bloomberg Beta, Founders Fund, Marcy Venture Partners, Union Square Ventures, VSC Ventures, Jeremy Yap.
Key people at Meatable.
# Meatable: High-Level Overview
Meatable is a Dutch biotech company developing cultivated meat technology that transforms animal cells into real meat products in a fraction of the time required by traditional farming. Founded in 2018 and headquartered in Delft, Netherlands, Meatable focuses on producing environmentally friendly, scalable cultivated meat through its proprietary Opti-Ox™ technology, which enables the differentiation of pluripotent stem cells into muscle and fat tissue in just four days[1][2]. The company serves the global meat industry and consumers seeking sustainable protein solutions without animal slaughter or significant environmental impact.
Meatable's core mission addresses critical societal challenges: significantly reducing greenhouse gas emissions, land use, and water consumption compared to conventional livestock farming[7]. The company has raised $95 million in funding, including a $35 million Series B round, and is advancing toward commercialization with plans to launch in Singapore and expand to the US market[3]. By solving the cultivated meat industry's central challenge—producing high-quality meat rapidly and cost-effectively at scale—Meatable positions itself as a critical infrastructure provider for the future of protein production.
# Origin Story
Meatable was founded in 2018 by Krijn de Nood (CEO, former McKinsey executive), Daan Luining (Co-founder and CTO, cultivated meat expert), and Dr. Mark Kotter (from Bit Bio)[6]. The company emerged from a recognition that existing cultivated meat approaches were inefficient and relied on problematic inputs like fetal bovine serum (FBS), harvested from cattle fetuses[5].
From inception, Meatable differentiated itself by adopting an ethical approach: sourcing cells from a single umbilical cord sample without harming animals[5]. The company achieved early traction by developing and publicly showcasing its first pork sausage product in 2022, with founders tasting the product and confirming viability toward a 2025 launch[5]. A pivotal moment came in October 2024 when Meatable was named to TIME's Best Inventions of 2024 list, recognizing its Opti-Ox™ technology as a game-changing innovation[2]. Most recently, the company acquired Uncommon Bio's cultivated meat platform, gaining complementary RNA delivery technology to expand into new species and strengthen its product pipeline[4].
# Core Differentiators
# Role in the Broader Tech Landscape
Meatable operates at the intersection of biotech innovation, food security, and climate solutions—three converging mega-trends reshaping global infrastructure. The cultivated meat industry addresses urgent pressures: global protein demand is projected to surge as populations grow, while conventional livestock farming consumes vast resources and drives significant greenhouse gas emissions.
The timing is critical. Regulatory pathways for cultivated meat are opening in major markets: Singapore approved cultivated meat for sale in 2020, and the US is advancing novel food approvals[3]. Meatable's breakthrough in production speed directly addresses the industry's central bottleneck—cost and time to commercialization—making it a foundational technology provider rather than merely a consumer brand. By licensing its platform to established meat producers, Meatable can influence the entire industry's transition to cultivated protein, amplifying its impact beyond direct product sales.
The company also signals a maturation of the cultivated meat ecosystem. Early-stage companies focused on proof-of-concept; Meatable represents the next wave: engineering-driven firms solving manufacturing challenges at scale. Its acquisition of Uncommon Bio's technology demonstrates consolidation and specialization within the sector, strengthening competitive moats.
# Quick Take & Future Outlook
Meatable is positioned as a critical infrastructure play in the protein transition. While consumer adoption of cultivated meat remains nascent, the company's technology addresses the fundamental economics that will determine industry viability. The four-day production cycle and non-GMO approach create defensible advantages in a regulatory environment where food safety and transparency are paramount.
Looking ahead, Meatable's trajectory hinges on three factors: (1) regulatory expansion beyond Singapore and the US, particularly in Europe and Asia; (2) licensing partnerships with established meat producers, which could accelerate adoption far beyond direct sales; and (3) cost parity with conventional meat, which the company claims its technology enables but has not yet demonstrated at commercial scale.
The company's 2025-2026 period will be defining. Successful launches in Singapore and the US, coupled with announced product expansions into beef and chicken, will validate whether Meatable's technology translates from pilot to production. If successful, Meatable could become the foundational platform upon which the cultivated meat industry scales—transforming from a startup into essential infrastructure for global protein production.
Meatable has raised $92.0M across 4 funding rounds. Most recently, it raised $34.0M Series B in August 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2023 | $34.0M Series B | BlueYard Capital, ZAKA Ventures | |
| Mar 1, 2021 | $47.0M Series A | BlueYard Capital, ZAKA Ventures | |
| Dec 1, 2019 | $7.0M Seed | Bloomberg Beta, Founders Fund, Marcy Venture Partners, Union Square Ventures, VSC Ventures, Jeremy Yap | |
| Sep 1, 2018 | $4.0M Seed | BlueYard Capital, ZAKA Ventures |
